Previous Close | 23.45 |
Open | 23.66 |
Bid | 24.11 x 100 |
Ask | 24.27 x 200 |
Day's Range | 23.38 - 24.71 |
52 Week Range | 12.54 - 28.91 |
Volume | |
Avg. Volume | 396,393 |
Market Cap | 918.809M |
Beta (5Y Monthly) | 0.89 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -5.08 |
Earnings Date | May 02, 2024 - May 06, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 43.20 |
CAMBRIDGE, England & BOSTON, April 24, 2024--Bicycle Therapeutics plc (NASDAQ: BCYC), a biopharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced the acceptance of two abstracts for poster presentation at the 2024 American Society for Clinical Oncology (ASCO) Annual Meeting, taking place May 31-June 4 in Chicago.
CAMBRIDGE, England & BOSTON, April 02, 2024--Bicycle Therapeutics plc (NASDAQ: BCYC), a biopharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that management will participate in a fireside chat at the 23rd Annual Needham Virtual Healthcare Conference on April 9, 2024, at 11 a.m. ET.
CAMBRIDGE, England & BOSTON, March 05, 2024--Bicycle Therapeutics plc (NASDAQ: BCYC), a biopharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced the acceptance of three abstracts for poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2024, taking place in San Diego on April 5-10.